I'm LongbridgeAI, I can summarize articles.Twist Bioscience (TWST) rose 5.4% this week to close at $139.92, outperforming the S&P 500 by about 5.87 percentage points. Trading was highly volatile, with an intraweek range of 16.48%. The stock gapped higher on Monday, touched $153.80 midweek, then lost momentum on Thursday before recovering to $139.92 on Friday, leaving a pattern of a midweek spike followed by stabilisation.
The Week
Twist Bioscience (TWST) rose 5.4% this week to close at $139.92, outperforming the S&P 500 by about 5.87 percentage points. Trading was highly volatile, with an intraweek range of 16.48%. The stock gapped higher on Monday, touched $153.80 midweek, then lost momentum on Thursday before recovering to $139.92 on Friday, leaving a pattern of a midweek spike followed by stabilisation.
Key Events
News flow this week centred on pre-market and after-hours swings, reflecting heightened sensitivity to interest rates and financing risk. TWST fell 3.41% in Tuesday’s pre-market, 3.29% in Wednesday’s, then dropped 3.44% after hours on Thursday and a further 5.85% before Friday’s open. Separate reports noted government funding continuing to flow into the sector, yet the basket of related names still traded lower. On a company level there were no material product, earnings or regulatory developments, so the week’s moves were driven mainly by macro sentiment and financing expectations.
Analyst Ratings
Among 13 brokers covering Twist Bioscience, 7 rate it buy, 2 rate it overweight, 3 rate it hold and 1 rates it sell. The consensus recommendation is buy, with a consensus target of $168.25, about 20.25% above the latest close of $139.92. Target prices range from $45.00 to $215.00, a wide spread that points to divergent views. Within the biotechnology sector, the stock ranks 90th out of 511 names for analyst rating.
The Week Ahead
A dense run of US macro data lands next week: the Dallas Fed manufacturing index on 26 October, followed on 27 October by durable goods orders, FHFA house prices, Case Shiller home prices, new home sales and consumer confidence. On the company side, Twist Bioscience is scheduled to report fiscal 2026 annual results on 13 November, with the market looking for a loss of $1.6721 per share on revenue of $456 million.
In Short
The stock spiked and pulled back this week but still closed higher, pointing to active two-way positioning. Broker ratings lean positive and the consensus target sits roughly 20% above spot, though the very wide target range signals real disagreement about the path ahead. The latest session’s flows show large-lot money as a net seller while smaller lots were net buyers. The next test is the annual report in November, alongside whether financing-rate expectations keep driving volatility.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.